Program
sitagliptin
Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 780 open or running | phase 4since Jan 28, 2009 | Jul 2, 2004 | none ahead |
| Ono Pharmaceutical | 50 open or running | phase 3since Aug 11, 2006 | Aug 11, 2006 | none ahead |
| ADIUM | 40 open or running | no phasesince Aug 10, 2026 | Aug 10, 2026 | none ahead |
| Novo Nordisk | 40 open or running | phase 4since Jan 24, 2012 | Jun 18, 2008 | none ahead |
| Bio-innova | 22 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Novartis | 20 open or running | phase 4since Sep 13, 2012 | Jun 12, 2012 | none ahead |
| Profil Institut für Stoffwechselforschung | 20 open or running | phase 2since Aug 28, 2013 | Aug 28, 2013 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 1since Jun 30, 2016 | Jun 30, 2016 | none ahead |
| dong-wha-pharmaceutical-co-ltd | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| getz-pharma | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| kinemed | 10 open or running | no phasesince Mar 23, 2010 | Mar 23, 2010 | none ahead |
Also a collaborator on its studies: parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Aug 6, 2008.
- Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01760447 · 223 enrolled
- Jul 22, 2013Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01907854 · 407 enrolled · United States, Canada, Hungary and more
- Aug 28, 2013Profil Institut für Stoffwechselforschung's first study: phase 2 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT01936025 · 34 enrolled · Germany
- Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02099110 · 1,233 enrolled
- Dec 12, 2014Phase 4 study in Diabetes Mellitus, Type 2Merck · NCT02318693 · 53 enrolled
- Aug 25, 2015Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02532855 · 614 enrolled
- Apr 11, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02738879 · 746 enrolled
- Jun 1, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02791490 · 458 enrolled
- Jun 30, 2016Chong Kun Dang Pharmaceutical's first study: phase 1 study in Diabetes Mellitus, Type 2New to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02827890 · 20 enrolled · Korea, Republic of
- Nov 24, 2017Phase 2 study in Pharmacological ActionProfil Institut für Stoffwechselforschung · NCT03359590 · 20 enrolled · Germany
- Nov 29, 2021getz-pharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to getz-pharmagetz-pharma · NCT05167513 · 188 enrolled · Pakistan
- May 4, 2022dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Healthy SubjectsNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT05403281 · 41 enrolled · Korea, Republic of
- Dec 15, 2023Bio-innova's first studies: 2 phase 1 studies in Healthy SubjectsNew to Bio-innovaBio-innova · NCT06233240, NCT06233201
- Aug 10, 2026ADIUM's first studies: 4 no phase studiesNew to ADIUMADIUM · NCT07763964, NCT07763951, NCT07763912 and 1 more
TargetBeta
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07763964Bioequivalance · Mexico | – | Completed | ADIUM | Dec 19, 2025 | 46 |
| NCT07763951Bioequivalance · Mexico | – | Completed | ADIUM | Dec 14, 2025 | 46 |
| NCT07763912Bioequivalence · Mexico | – | Completed | ADIUM | Dec 5, 2025 | 46 |
| NCT07763899Bioequivalance · Mexico | – | Completed | ADIUM | Nov 30, 2025 | 46 |
| NCT06233240Healthy Subjects | 1 | Not yet recruiting | Bio-innova | May 29, 2024 | 34 |
| NCT06233201Healthy Subjects | 1 | Not yet recruiting | Bio-innova | Jul 14, 2024 | 34 |
| NCT05403281Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Dec 3, 2021 | 41 |
| NCT05167513Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | getz-pharma | Apr 28, 2022 | 188 |
| NCT03359590Pharmacological Action · Germany | 2 | Completed | Profil Institut für Stoffwechselforschung | Jul 17, 2019 | 20 |
| NCT02827890Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 20 |
| NCT02791490Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Feb 1, 2018 | 458 |
| NCT02738879Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jan 22, 2018 | 746 |
| NCT02532855Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 10, 2017 | 614 |
| NCT02318693Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Dec 15, 2015 | 53 |
| NCT02099110Diabetes Mellitus, Type 2 | 3 | Completed | Merck | May 26, 2016 | 1,233 |
| NCT01936025Diabetes Mellitus, Type 2 · Germany | 2 | Completed | Profil Institut für Stoffwechselforschung | Apr 2014 | 34 |
| NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more | 4 | Completed | Novo Nordisk | Jun 15, 2015 | 407 |
| NCT01760447Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Sep 17, 2019 | 223 |
| NCT01702298Diabetes Mellitus, Type 2 | 3 | Completed | Merck | May 29, 2013 | 42 |
| NCT01686932Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Novartis | Sep 2014 | 51 |
| NCT01678820Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Nov 1, 2013 | 299 |
| NCT01619332Diabetes Mellitus, Type 2 · United States | 2 | Completed | Novartis | Sep 2013 | 220 |
| NCT01590797Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 11, 2014 | 467 |
| NCT01590771Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 10, 2014 | 498 |
| NCT01582308Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Dec 4, 2012 | 22 |
| NCT01557504Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Apr 29, 2014 | 25 |
| NCT01519674Diabetes Mellitus · Argentina, Australia, Brazil and more | 4 | Completed | Novo Nordisk | Oct 2013 | 582 |
| NCT01485614Diabetes Mellitus | 3 | Completed | Merck | Oct 9, 2019 | 200 |
| NCT01477853Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Dec 4, 2012 | 166 |
| NCT01517321Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Ono Pharmaceutical | ||
| NCT01462266Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 6, 2013 | 660 |
| NCT01405911Glucose Intolerance | 2 | Completed | Merck | Apr 9, 2012 | 242 |
| NCT01340768Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Sep 21, 2011 | 870 |
| NCT01296412Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Feb 29, 2012 | 653 |
| NCT01189890Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 31, 2012 | 480 |
| NCT01177384Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Mar 25, 2013 | 380 |
| NCT01131182Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Nov 4, 2010 | 1,147 |
| NCT01092663Diabetes Mellitus, Type 2 · United States | – | Completed | kinemed | Jul 2011 | 61 |
| NCT01093794Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jun 2010 | 28 |
| NCT01076088Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Dec 24, 2012 | 744 |
| NCT01076075Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jul 11, 2011 | 427 |
| NCT01046110Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Nov 2010 | 458 |
| NCT01034111Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 4, 2010 | 30 |
| NCT01028391Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jan 1, 2009 | 317 |
| NCT00993187Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Oct 29, 2013 | 292 |
| NCT00975052Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Mar 2006 | 16 |
| NCT00944450Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Sep 2004 | 12 |
| NCT00929201Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Mar 2008 | 61 |
| NCT00888238Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jun 10, 2009 | 12 |
| NCT00885352Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Nov 10, 2010 | 313 |
| NCT00875394Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 27, 2008 | 68 |
| NCT00854035Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Ono Pharmaceutical | Jun 2010 | 266 |
| NCT00833027Diabetes Mellitus | 4 | Completed | Merck | Oct 30, 2009 | 608 |
| NCT00832624Diabetes Mellitus, Type 2 | 4 | Terminated | Merck | Sep 2, 2009 | 10 |
| NCT00832390Diabetes Mellitus | 4 | Completed | Merck | Jul 11, 2008 | 29 |
| NCT00830076Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Apr 30, 2009 | 18 |
| NCT00813995Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Aug 9, 2010 | 395 |
| NCT00790205Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Mar 30, 2015 | 14,671 |
| NCT00758069Diabetes Mellitus, Type 2 | 2 | Completed | Merck | Feb 13, 2006 | 80 |
| NCT00730275Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Dec 30, 2010 | 35 |
How it is read
Names in the registry
- “Sitagliptin”, 33 entries
- “sitagliptin phosphate”, 18 entries
- “sitagliptin”, 15 entries
- “Sitagliptin phosphate”, 10 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: MK0431.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 106 studies
- Diabetes Mellitus, 2 studies
- Glucose Intolerance, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.